DJIA 17,106.70 29.83 0.17%
NASDAQ 4,570.64 0.00 0.00%
S&P 500 2,000.02 2.10 0.11%
market minute promo

Emergent BioSolutions (NYSE: EBS)



company name or ticker

Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape

Emergent Rises on Cangene Deal - Analyst Blog

Emergent BioSolutions Announces Positive Phase 1b Otlertuzumab Results in Combination with Rituximab

Emergent BioSolutions Announces Positive Phase 1b Otlertuzumab Results in Combination with Rituximab in People with CLL

Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination

Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia

Emergent BioSolutions' Management Presents at Credit Suisse Healthcare Conference (Transcript)

Emergent BioSolutions' CEO Discusses Q3 2013 Results - Earnings Call Transcript

Emergent BioSolutions Inc. Discusses Q3 2013 Results (Webcast)

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Investing in Counteracting Biological and Chemical Agents

Biological and chemical agents are a lethal scourge of war, but Emergent Biosciences is developing countermeasures to a wide range of such agents.

Emergent Biosciences Finally Expanding Beyond Anthrax